Study suggests lean muscle mass loss can be minimized during weight loss therapy using newer incretin obesity drugs

New research to be presented at the European Congress on Obesity (ECO 2025, Malaga, Spain, 11–14 May) shows that patients using GLP-1 or combined GLP-1 / GIP receptor agonist therapy for weight loss experienced minimal lean muscle mass loss as they lost weight across six months of treatment.

This article was originally published on MedicalXpress.com

You may also be interested in:

Read More:

Lawyers Lookup